Trial readouts
Phase II/III results, regulatory decisions and discontinuations in PD therapeutics.
State of the art
No update yet for Trial readouts. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease
Provides the definitive peer-reviewed record of a terminated Phase 1/2 open-label dopamine gene therapy trial (n=6, two dose cohorts), previously documented only in press releases and conference abstracts — a key data-preservation step for informing successor trial designs. -
バイオジェンとデナリ、パーキンソン病治療薬の開発を中止 執筆 - Investing.com - FX | 株式市場 | ファイナンス | 金融ニュース
The Phase 2b LUMA study is a high-profile negative readout: BIIB122 met neither its primary endpoint (time to confirmed worsening on MDS-UPDRS Parts II+III combined) nor any secondary endpoints, resulting in programme discontinuation for idiopathic Parkinson's disease. Full data are to be presented at an upcoming scientific conference. -
Safety and efficacy of faecal microbiota transplantation in Parkinson’s disease
This 2026 review synthesises results from five FMT randomised controlled trials in Parkinson's, highlighting a critical methodological problem: donor selection, delivery route, pre-treatment, and follow-up duration varied so widely that cross-trial comparison is unreliable. The authors argue this heterogeneity — not a lack of biological signal — is the main obstacle to a definitive answer, and call for larger, protocol-standardised RCTs. -
Vyalev eases motor, nonmotor symptoms in advanced Parkinson’s
Six-month interim results from ROSSINI (NCT06107426), an AbbVie-funded 10-country observational study of 427 adults, were published in Neurology and Therapy and represent the first prospective real-world readout for Vyalev; a 12-month interim analysis in 200 patients is planned next. -
Tolerability and efficacy of full-body head-up tilt sleeping in Parkinson’s disease and multiple system atrophy
The Heads-Up trial (NCT05551377) reports its primary tolerability and efficacy results: a non-pharmacological, positional intervention reached its proof-of-concept endpoints in a 20-person PD/MSA cohort, with measurable blood-pressure benefits at moderate bed angles. The trial was funded by the Michael J. Fox Foundation and establishes the dose-response and tolerability profile needed to design a larger efficacy study.